4.7 Article

Factor structure and dimensionality of the two depression scales in STAR*D using level 1 datasets

Journal

JOURNAL OF AFFECTIVE DISORDERS
Volume 132, Issue 3, Pages 396-400

Publisher

ELSEVIER
DOI: 10.1016/j.jad.2011.03.011

Keywords

Hamilton depression scale; Inventory of Depressive Symptomatology; Principal component analysis; Item response theory analysis

Funding

  1. Astra-Zeneca
  2. Lilly
  3. H Lundbeck A/S
  4. Organon
  5. Abbott Laboratories
  6. Alkermes, Inc.
  7. Aspect Medical Systems
  8. AstraZeneca
  9. BioResearch
  10. BrainCells Inc.
  11. Bristol-Myers Squibb
  12. Cephalon, Inc.
  13. Clinical Trials Solutions, LLC
  14. Covidien
  15. Eli Lilly and Company
  16. En Vivo Pharmaceuticals, Inc.
  17. Forest Pharmaceuticals, Inc.
  18. Ganeden Biotech, Inc.
  19. GlaxoSmithKline
  20. Johnson & Johnson Pharmaceutical Research Development
  21. Lichtwer Pharma GmbH
  22. Lorex Pharmaceuticals
  23. Novartis AG
  24. Organon Pharmaceuticals
  25. PamLab, LLC.
  26. Pfizer Inc.
  27. Pharmavite(R) LLC
  28. Roche
  29. RTC Logic, LLC
  30. Sanofi-Aventis US LLC
  31. Shire
  32. Solvay Pharmaceuticals, Inc.
  33. Solvay Pharmaceuticals, Inc.
  34. Synthelabo
  35. Wyeth-Ayerst Laboratories
  36. Agency for Healthcare Research and Quality (AHRQ)
  37. Corcept Therapeutics, Inc.
  38. Cyberonics, Inc.
  39. Merck
  40. National Alliance for Research in Schizophrenia and Depression
  41. National Institute of Mental Health
  42. National Institute on Drug Abuse
  43. Novartis
  44. Pharmacia Upjohn
  45. Predix Pharmaceuticals (Epix)
  46. Targacept
  47. Abbott Laboratories, Inc.
  48. Abdi Ibrahim
  49. Akzo (Organon Pharmaceuticals Inc.)
  50. Bristol-Myers Squibb Company
  51. Evotec
  52. Fabre Kramer Pharmaceuticals, Inc.
  53. Forest Pharmaceuticals
  54. Janssen Pharmaceutica Products
  55. LP
  56. Johnson Johnson PRD
  57. Eli Lilly Company
  58. Meade Johnson
  59. Medtronic
  60. Neuronetics
  61. Otsuka Pharmaceuticals
  62. Parke-Davis Pharmaceuticals, Inc.
  63. Sepracor
  64. SHIRE Development
  65. VantagePoint
  66. National Alliance for Research on Schizophrenia and Depression (NARSAD)
  67. National Institutes of Health

Ask authors/readers for more resources

Background: The factor structure and dimensionality of the HAM-D-17 and the IDS-C-30 are as yet uncertain, because psychometric analyses of these scales have been performed without a clear separation between factor structure profile and dimensionality (total scores being a sufficient statistic). Methods: The first treatment step (Level 1) in the STAR*D study provided a dataset of 4041 outpatients with DSM-IV nonpsychotic major depression. The HAM-D-17 and IDS-C-30 were evaluated by principal component analysis (PCA) without rotation. Mokken analysis tested the unidimensionality of the IDS-C-6, which corresponds to the unidimensional HAM-D-6. Results: For both the HAM-D-17 and IDS-C-30, PCA identified a bi-directional factor contrasting the depressive symptoms versus the neurovegetative symptoms. The HAM-D-6 and the corresponding IDS-C-6 symptoms all emerged in the depression factor. Both the HAM-D-6 and IDS-C-6 were found to be unidimensional scales, i.e., their total scores are each a sufficient statistic for the measurement of depressive states. Limitations: STAR*D used only one medication in Level 1. Conclusions: The unidimensional HAM-D-6 and IDS-C-6 should be used when evaluating the pure clinical effect of antidepressive treatment, whereas the multidimensional HAM-D-17 and IDS-C-30 should be considered when selecting antidepressant treatment. (C) 2011 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available